Document:

EX-10.2

 Exhibit 10.2 

ESCROW AGREEMENT 
 THIS
ESCROW AGREEMENT dated as of May 9th, 2018 (this “Agreement”), is entered into by and among Oaktree Real Estate Income Trust, Inc., a Maryland corporation (the “Company”) and UMB Bank, N.A., as escrow agent (the
“Escrow Agent”). 
 WHEREAS, the Company is registering for sale in a public offering a maximum of $2,000,000,000
(consisting of up to $1,600,000,000 in the Company’s primary offering and up to $400,000,000 in shares pursuant to the Company’s distribution reinvestment plan) in shares of its common stock, $0.01 par value per share, consisting of
Class T common stock, Class S common stock, Class D common stock, and Class I common stock (collectively, the “Shares”), pursuant to the Company’s Registration Statement on Form S-11 (File No. 333-223022) (the “Offering”); 

WHEREAS, the Company will prepare a prospectus, as the same may be amended and supplemented from time to time (the
“Prospectus”), and the offer and sale of Shares will be made pursuant to the terms and conditions contained in the Prospectus; 

WHEREAS, the SDDco Brokerage Advisors, LLC, a New York limited liability company, as dealer manager for the Company (the “Dealer
Manager”) has been engaged by the Company pursuant to a Dealer Manager Agreement dated February 16, 2018 (as amended from time to time, the “Dealer Manager Agreement”) to offer and sell the Shares on a best efforts
basis in the Offering through a network of participating broker-dealers (the “Dealers”); 
 WHEREAS, pursuant to the Dealer
Manager Agreement, the Dealer Manager has agreed to deposit all proceeds from the Offering to the Escrow Agent prior to the Offering meeting the minimum offering contingency described in the Prospectus; 

WHEREAS, the Company desires to establish an Escrow Account (defined below) as further described herein and to deposit funds contributed by
subscribers subscribing to purchase Shares (“Subscribers”) with the Escrow Agent in the Escrow Account, to be held for the benefit of the Subscribers and the Company until such time as subscriptions for the Minimum Amount (as
defined below) has been deposited into the Escrow Account in accordance with the terms of this Agreement; 
 WHEREAS, at the direction of
the Company, DST Systems, Inc. (the “Processing Agent”) has been engaged to receive, examine for “good order” and facilitate subscriptions into the Escrow Account as further described herein and to act as record keeper,
maintaining on behalf of the Escrow Agent the ownership records for the Escrow Account; and 
 WHEREAS, the Escrow Agent is willing to
accept appointment as escrow agent for the Offering upon the express terms and conditions set forth herein. 
 NOW, THEREFORE, in
consideration of the foregoing and of the mutual covenants and agreements contained herein, the parties hereto, intending to be legally bound, hereby agree as follows: 

 1.    Escrow of Subscriber Funds. 

(a)     On or before the commencement of the Offering, the Company shall establish an interest bearing deposit account with
the Escrow Agent to be invested in accordance with Section 7 hereof entitled “UMB BANK, N.A., AS ESCROW AGENT FOR OAKTREE REAL ESTATE INCOME TRUST, INC.” (the “Escrow Account”). All funds received from Subscribers in
payment for the Shares (“Subscriber Funds”) which comply with the instructions set forth in Section 1(c) will be sent to the Escrow Agent promptly following the day upon which such Subscriber Funds are received by the
Processing Agent and such subscription is accepted by the Company, and shall, upon receipt by the Escrow Agent, be retained in the Escrow Account by the Escrow Agent and invested as stated herein. The Company shall also instruct its agents
(including the Dealer Manager) to promptly deliver funds to the Escrow Agent immediately upon their receipt of such funds. During the term of this Agreement, which shall begin on the date hereof, the Company or its agents (including the Dealer
Manager) shall cause all checks received by and made payable to it in payment for the Shares to be endorsed in favor of the Escrow Agent and delivered to the Escrow Agent for deposit. Subscriber Funds may also be wired directly to the Escrow Account
using wire instructions provided by the Escrow Agent. Such Subscriber Funds shall be retained in the Escrow Account by the Escrow Agent and invested as set forth in Section 7 and shall be deposited within one business day of receipt. 

(b)     The Escrow Agent shall have no duty to make any disbursement, investment or other use of Subscriber Funds until
and unless it has good and collected funds. If any checks deposited in the Escrow Account are returned or prove uncollectible after the funds represented thereby have been released by the Escrow Agent, then the Company shall promptly reimburse the
Escrow Agent for its reasonable and documented costs incurred for such, if any, upon request, and the Escrow Agent shall deliver the returned checks to the Company. The Escrow Agent shall be under no duty or responsibility to enforce collection of
any check delivered to it hereunder. 
 (c)    Until such time as the Company has received subscriptions for Shares
resulting in gross subscription proceeds equal to the Minimum Offering (as defined below) and the funds in the Escrow Account are disbursed from the Escrow Account in accordance with Section 2(c) hereof, Subscribers will be instructed by the
Company to remit the purchase price in the form of checks drafts, wires, Automated Clearing House (ACH) or money orders (hereinafter, “Instruments of Payment”) payable to the order of “UMB Bank, N.A., as Escrow Agent for
Oaktree Real Estate Income Trust, Inc.” Any Instruments of Payment made payable to a party other than as set forth above shall be returned to the Dealer Manager or the Dealer who submitted the check. The Company, in its sole and absolute
discretion, may reject any Subscriber subscription for any reason. 
 2.    Operation of the Escrow. 

(a)     Completed subscription agreements and Instruments of Payment for the purchase price will be remitted by Subscribers
to a Dealer at the address designated for the receipt of such agreements and Instruments of Payment. 

  
 2 

 (b)     When a Dealer’s internal supervisory procedures are conducted at
the site at which the Instruments of Payment and the Subscription Materials (as defined below) are initially received by the Dealer, by the end of the next business day after receipt of any Instruments of Payment and Subscription Materials, such
Dealer will send to the Processing Agent such Instruments of Payment along with each Subscriber’s name, address, executed IRS Form W-9, number and class of Shares purchased and purchase price remitted and
any other subscription documentation (the “Subscription Materials”). When a Dealer’s internal supervisory procedures are conducted at a different location (the “Final Review Office”), such Dealer shall transmit
the Instruments of Payment and the Subscription Materials to the Final Review Office by the end of the next business day after receipt of any Instruments of Payment and Subscription Materials, and then the Final Review Office will, by the end of the
next business day following its receipt of the Instruments of Payment and the Subscription Materials, forward the Instruments of Payment and the Subscription Materials to the Processing Agent. To the extent that subscription agreements and payments
are remitted by the Processing Agent, the Company, the Dealer Manager or a Dealer, the Processing Agent, the Company, the Dealer Manager or a Dealer, as applicable, will furnish to the Escrow Agent a list detailing information regarding such
subscriptions as set forth in Exhibit A. The Processing Agent will promptly deliver all monies received in good order from Subscribers (or from the Company, the Dealer Manager or Dealers transmitting monies and subscriptions from Subscribers)
for the payment of Shares to the Escrow Agent for deposit in the Escrow Account. Deposits shall be held in the Escrow Account until such funds are disbursed in accordance with this Section 2. Prior to disbursement of the funds deposited in the
Escrow Account, such funds shall not be subject to claims by creditors of the Company or any of its affiliates. If any of the Instruments of Payment are returned to the Escrow Agent for nonpayment prior to the satisfaction of the Minimum Amount, the
Escrow Agent shall promptly notify the Processing Agent and the Company in writing via mail or email of such nonpayment, and the Escrow Agent is authorized to debit the Escrow Account, as applicable, in the amount of such returned payment as well as
any interest earned on the amount of such payment and the Processing Agent shall delete the appropriate account from the records maintained by the Processing Agent. The Processing Agent will maintain a written account of each sale, which account
shall set forth, among other things, the following information: (i) the Subscriber’s name and address, (ii) the number and class of Shares purchased by such Subscriber, and (iii) the amount paid by such Subscriber for such
Shares. Prior to the satisfaction of the Minimum Amount, the Company will not be entitled to any funds received into the Escrow Account. Notwithstanding the foregoing, prior to the satisfaction of the Minimum Amount, upon the written request of a
Subscriber (which may be delivered by the Company or Dealer Manager) to withdraw their purchase order and request a full refund, the Escrow Agent shall, subject to Section 7(c) below, disburse directly to such Subscriber the principal amount of
the subscription payment from such Subscriber received by the Escrow Agent plus any interest accrued thereon. 

  
 3 

 (c)    If at any time on or prior to the Expiration Date (as defined below),
(i) the subscription proceeds received by the Escrow Agent are equal to or greater than $150,000,000, including Shares purchased by the Company’s sponsor, its affiliates and the Company’s officers and directors (“Minimum
Amount”) and (ii) the Company’s board of directors has authorized the release to the Company of all Subscriber Funds in the Escrow Account, then the Company shall deliver to the Escrow Agent a written instruction from an officer
of the Company stating that the Minimum Amount has been timely raised and authorizing the delivery of all Subscriber Funds in the Escrow Account to the Company. Thereafter, the Escrow Agent shall promptly disburse to the Company, by check or wire
transfer (i) the funds in the Escrow Account representing the principal amount of the gross subscription payments from Subscribers received by the Escrow Agent and (ii) any interest accrued thereon; provided, however, that
the Escrow Agent shall not disburse those funds of a Subscriber whose subscription has been rejected or rescinded of which the Escrow Agent has been notified in writing by the Company, or otherwise in accordance with the Company’s written
request. 
 (d)    After the Escrow Agent has disbursed the funds from the Escrow Account in accordance with this
Section 2, in the event that the Company receives subscriptions made payable to the Escrow Agent, the proceeds shall not be subject to the restrictions set forth in this Agreement, and the Escrow Agent shall notify the Company of the receipt of
such proceeds and such proceeds shall be disbursed as directed in writing by the Company; provided upon the termination of this Agreement, the Escrow Agent shall have no obligation to accept any such proceeds. 

(e)    If, as of the close of business on the one year anniversary of the commencement of the Offering (the
“Expiration Date”), the funds in the Escrow Account do not equal or exceed the Minimum Amount (or, even if the Minimum Amount is met, the Company notifies the Escrow Agent that the Company’s board of directors has not
authorized the release to the Company of all Subscriber Funds in the Escrow Account), within 10 days following the Escrow Agent’s receipt of written notice from the Company of the Expiration Date, the Escrow Agent shall promptly return
directly to each Subscriber (i) by check or wire transfer, the Subscriber Funds deposited in the Escrow Account on behalf of such Subscriber (unless earlier disbursed in accordance with this Agreement), or (ii) the Instruments of Payment
delivered to the Escrow Agent with respect to such Subscriber’s subscription if such Instrument of Payment has not been processed for collection prior to such time, in either case, together with any interest income thereon. Notwithstanding the
above, in the event the Escrow Agent has not received an executed IRS Form W-9 at such time for each Subscriber, the Escrow Agent shall remit an amount to the Subscribers in accordance with the provisions
hereof, withholding the applicable percentage for backup withholding required by the Internal Revenue Code, as then in effect, from any interest income on subscription proceeds attributable to each Subscriber for whom the Escrow Agent does not
possess an executed IRS Form W-9. However, the Escrow Agent shall not be required to remit any payments until the Escrow Agent has collected funds represented by such payments. 

  
 4 

 (f)    The Company shall, or shall cause the Processing Agent or the Dealer
Manager to, furnish to the Escrow Agent with each delivery of an Instrument of Payment, a list of the Subscribers who have paid for the Shares showing the name, address, tax identification number, amount and class of Shares subscribed for and the
amount paid and deposited with the Escrow Agent. This information comprising the identity of Subscribers shall be provided to the Escrow Agent in the format set forth on Exhibit A to this Agreement (the “List of
Subscribers”). All Subscriber Funds deposited in the Escrow Account shall not be subject to any liens or charges by the Company or the Escrow Agent, or judgments or creditors’ claims against the Company, until and unless released to
the Company as hereinafter provided. The Company understands and agrees that the Company shall not be entitled to any Subscriber Funds on deposit in the Escrow Account and no such funds shall become the property of the Company except when released
to the Company pursuant to this Agreement. The Escrow Agent will treat all Subscriber information as confidential and will not use the information provided to it by the Company for any purpose other than to fulfill its obligations as Escrow Agent;
provided the Escrow Agent may disclose Subscriber information to the extent required by applicable law or to the extent required by a supervisory or governmental authority or a self-regulatory organization pursuant to any examination, inquiry, or
audit of the Escrow Agent. 
 3.    Rejected Subscriptions. If the Escrow Agent receives written notice from the
Company or the Dealer Manager that the Company has rejected a Subscriber’s subscription, the Escrow Agent shall, subject to Section 7(c) below, pay directly to the applicable Subscriber(s), within a reasonable time not to exceed 10
business days after receiving notice of the rejection, by first class United States Mail at the address appearing on the List of Subscribers, or at such other address or wire instructions as are furnished to the Escrow Agent by the Subscriber in
writing, all collected sums paid by the Subscriber for Shares and received by the Escrow Agent together with all interest earned thereon. 

4.    Termination of Escrow Agreement. Unless otherwise provided in this Agreement, final termination of this
Agreement shall occur on the earliest of the date that (a) all funds held in the Escrow Account are distributed either to the Company or to Subscribers and the Company has informed the Escrow Agent in writing to close the Escrow Account,
(b) all funds held in the Escrow Account are distributed to a successor escrow agent upon written instructions from the Company or (c) the Escrow Agent receives written notice from the Company that the Company terminated the Offering and
any funds held in the Escrow Account are distributed in accordance with this Agreement. After the termination of this Agreement, the Company shall not deposit, and the Escrow Agent shall not accept, any additional amounts representing payments by
prospective Subscribers. 
 5.    Duty and Liability of the Escrow Agent. 

(a)    The Escrow Agent’s rights and responsibilities shall be governed solely by this Agreement. The Escrow Agent
shall at all times comply with applicable securities or other laws in performing its duties pursuant to this Agreement provided the Escrow Agent shall be deemed in compliance with the foregoing and protected in relying upon the written direction of
the Company and shall have no independent obligation to evaluate whether an act or omission complies with applicable securities or other laws. The Escrow Agent shall be under no duty to determine whether the Company is complying with requirements of
this Agreement, the Offering 

  
 5 

 
or applicable securities or other laws in tendering the Subscriber Funds to the Escrow Agent. No other agreement shall be considered as adopted or binding, in whole or in part, upon the Escrow
Agent notwithstanding that any such other agreement may be referred to herein or deposited with the Escrow Agent or the Escrow Agent may have knowledge thereof, including specifically but without limitation any Offering documents (including the
subscription agreement and exhibits thereto), and the Escrow Agent’s rights and responsibilities shall be governed solely by this Agreement. 

(b)    The Escrow Agent shall not be responsible for or be required to enforce any of the terms or conditions of any
Offering document (including the subscription agreement and exhibits thereto) or other agreement between the Company and any other party. 

(c)    The Escrow Agent may conclusively rely upon and shall be protected in acting upon any statement, certificate,
notice, request, consent, order or other document reasonably believed by it to be genuine and to have been signed or presented by the proper party or parties. The Escrow Agent shall have no duty or liability to verify any such statement,
certificate, notice, request, consent, order or other document. Before or concurrently with the execution of this Agreement, the Company shall deliver to the Escrow Agent an authorized signers list in the form of Exhibit B to this Agreement.

 (d)    The Escrow Agent shall be under no obligation to institute or defend any action, suit or proceeding in
connection with this Agreement unless first indemnified to its reasonable satisfaction pursuant to the terms herein. The Escrow Agent may consult outside counsel of its own choice with respect to any question arising under this Agreement and the
Escrow Agent shall not be liable for any action taken or omitted in good faith upon the advice of such counsel. The Escrow Agent is authorized to perform any duties hereunder either directly or, with the Company’s consent, through its agents.
The Escrow Agent shall not be liable for any action taken or omitted by it in good faith except to the extent that a court of competent jurisdiction determines that the Escrow Agent’s gross negligence, recklessness or willful misconduct was the
primary cause of loss. 
 (e)    The Escrow Agent is acting solely as escrow agent hereunder and owes no duties,
covenants or obligations, fiduciary or otherwise, to any other person by reason of this Agreement, except as otherwise stated herein, and no implied duties, covenants or obligations, fiduciary or otherwise, shall be read into this Agreement against
the Escrow Agent. 
 (f)    If any disagreement between any of the parties to this Agreement, or between any of them and
any other person, including any Subscriber, resulting in adverse claims or demands being made in connection with the matters covered by this Agreement, or if the Escrow Agent is in reasonable doubt as to what action it should take hereunder, the
Escrow Agent may, at its option, refuse to comply with any claims or demands on it, or refuse to take any other action hereunder, so long as such disagreement continues or such reasonable doubt exists, and in any such event, the Escrow Agent shall
not be or become liable in any way or to any person for its failure or refusal to act, and the Escrow Agent shall be entitled to continue so to refrain from acting until (i) the rights of all interested parties shall have been fully and finally
adjudicated by a court of competent jurisdiction, or (ii) all differences shall have been adjudged and all reasonable doubt resolved by agreement among all of the interested persons, and the 

  
 6 

 
Escrow Agent shall have been notified thereof in writing signed by all such persons. Notwithstanding the foregoing, the Escrow Agent may in its discretion obey the order, judgment, decree or levy
of any court with jurisdiction and the Escrow Agent is hereby authorized in its sole discretion to comply with and obey any such orders, judgments, decrees or levies. If any controversy should arise with respect to this Agreement, the Escrow Agent
shall have the right, at its option, to institute an interpleader action in any court of competent jurisdiction to determine the rights of the parties. 

(g)    IN NO EVENT SHALL THE ESCROW AGENT BE LIABLE, DIRECTLY OR INDIRECTLY, FOR ANY SPECIAL, INDIRECT OR CONSEQUENTIAL
LOSSES OR DAMAGES OF ANY KIND WHATSOEVER (INCLUDING WITHOUT LIMITATION LOST PROFITS), EVEN IF THE ESCROW AGENT HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSSES OR DAMAGES AND REGARDLESS OF THE FORM OF ACTION. 

(h)    The parties agree that the Escrow Agent has no role in the preparation of the Offering documents (including the
subscription agreement and exhibits thereto) and makes no representations or warranties with respect to the information contained therein or omitted therefrom. 

(i)    The Escrow Agent shall have no obligation, duty or liability with respect to compliance with any federal or state
securities, disclosure or tax laws concerning the Offering documents (including the subscription agreement and exhibits thereto) or the issuance, offering or sale of the Shares. The Escrow Agent shall have no duty or obligation to monitor the
application and use of the Subscriber Funds once transferred to the Company, that being the sole obligation and responsibility of the Company. 

6.    Escrow Agent’s Fee. The Escrow Agent shall be entitled to compensation for its services as stated in the
fee schedule attached hereto as Exhibit C, which compensation shall be paid by or on behalf of the Company. The fee agreed upon for the services rendered hereunder is intended as full compensation for the Escrow Agent’s services as
contemplated by this Agreement; provided, however, that if the conditions for the disbursement of funds under this Agreement are not fulfilled, or the Escrow Agent renders any material service not contemplated in this Agreement, or if
there is, with the Company’s consent, any assignment of interest in the subject matter of this Agreement or any material modification hereof, or if any material controversy arises hereunder, or the Escrow Agent is made a party to any litigation
pertaining to this Agreement, or the subject matter hereof, then the Escrow Agent shall be reasonably compensated for such extraordinary services and reimbursed for its reasonable and documented out-of-pocket costs and expenses, including reasonable attorney’s fees, occasioned by any delay, controversy, litigation or event, and the same shall be recoverable from the Company. The Company’s
obligations under this Section 6 shall survive the resignation or removal of the Escrow Agent and the assignment or termination of this Agreement. 

7.    Investment of Subscriber Funds. 

(a)    The Escrow Agent shall promptly invest the Subscriber Funds, including any and all interest and investment income,
in accordance with the written instructions provided 

  
 7 

 
to the Escrow Agent and signed by the Company. In the absence of written investment instructions from the Company, the Escrow Agent shall deposit and invest the Subscriber Funds, including any
and all interest and investment income, in UMB Money Market Special, a UMB money market deposit account. Any interest received by the Escrow Agent with respect to the Subscriber Funds, including reinvested interest shall become part of the
Subscriber Funds, and shall be disbursed pursuant to this Agreement. The Company agrees that, for tax reporting purposes, all interest or other taxable income earned on the Subscriber Funds in any tax year shall be taxable to the to the person or
entity receiving the interest or other taxable income. Notwithstanding anything herein to the contrary, funds in the Escrow Account may only be invested in “Short Term Investments” in compliance with Rule
15c2-4 of the Securities Exchange Act of 1934, as amended. The Escrow Agent shall provide to the Company monthly statements (or more frequently as reasonably requested by the Company) on the account balance in
the Escrow Account and the activity in such account since the last report. 
 (b)    The Escrow Agent shall be entitled
to sell or redeem any such investments as the Escrow Agent deems necessary to make any payments or distributions required under this Agreement. The Escrow Agent shall have no responsibility or liability for any loss which may result from any
investment or sale of investment made pursuant to this Agreement. The parties acknowledge that the Escrow Agent is not providing investment supervision, recommendations, or advice. 

(c)    At any time interest income earned on Subscriber Funds deposited in the Escrow Account (“Escrow
Income”) is to be paid to a Subscriber pursuant to this Agreement, the Escrow Agent shall promptly provide directly to such Subscriber the amount of Escrow Income payable to such Subscriber; provided that the Escrow Agent is in
possession of such Subscriber’s executed IRS Form W-9. In the event an executed IRS Form W-9 is not received for each Subscriber the Escrow Agent shall have no
obligation to return Escrow Income to any Subscriber until after it has received an executed and valid IRS Form W-9 executed by the Subscriber and shall remit an amount to the Subscribers in accordance with
the provisions hereof, withholding the applicable percentage for backup withholding required by the Internal Revenue Code, as then in effect, from any Escrow Income attributable to those Subscribers for whom the Escrow Agent does not possess an
executed IRS Form W-9. Escrow Income shall be remitted to Subscribers at the address provided to the Escrow Agent in the List of Subscribers, which the Escrow Agent shall be entitled to rely upon, and without
any deductions for escrow expenses.  
 8.    Notices. All notices, requests, demands, and other
communications under this Agreement shall be in writing and shall be deemed to have been duly given (a) on the date of service if served personally on the party to whom notice is to be given, (b) on the day of transmission if sent by
facsimile/email transmission to the facsimile number/email address given below, and written confirmation of receipt is obtained promptly after completion of transmission, (c) on the business day after delivery to Federal Express or similar
overnight courier or the Express Mail service maintained by the United States Postal Service, or (d) on the fifth business 

  
 8 

 
day after mailing, if mailed to the party to whom notice is to be given, by first class mail, registered or certified, postage prepaid, and properly addressed, return receipt requested, to the
party as follows: 
 If to the Company: 

Oaktree Real Estate Income Trust, Inc. 

333 South Grand Avenue, 28th Floor 

Los Angeles, CA 90071 

Attention: Chief Securities Counsel 

Telephone: (213) 830-6300 

E-mail: OakREITNotices@oaktreeREIT.com 

If to Escrow Agent: 
 UMB
Bank, N.A. 
 204 North Robinson Ave 

2nd Floor 

Oklahoma City, Oklahoma 73103 

Attention: Janet Lambert, Corporate Trust & Escrow Services 

Telephone: (405) 239-5901 

Facsimile: (405) 516-1276 

Email: janet.lambert@umb.com 

Any party may change its address for purposes of this Section 8 by giving the other party written notice of the new address in the manner
set forth above. 
 9.    Indemnification of Escrow Agent. The Company shall indemnify, defend and hold harmless
the Escrow Agent from and against, any and all loss, liability, cost, damage and expense, including, without limitation, reasonable counsel fees and expenses (“Losses”), which the Escrow Agent may suffer or incur by reason of any
action, claim or proceeding brought against the Escrow Agent arising out of or relating in any way to this Agreement or any transaction to which this Agreement relates unless such Losses are finally determined by a court of competent jurisdiction to
have been caused by the negligence, recklessness or willful misconduct of the Escrow Agent. The terms of this Section 9 shall survive the termination of this Agreement and the resignation or removal of the Escrow Agent. 

10.    Successors and Assigns. Except as otherwise provided in this Agreement, no party hereto shall assign this
Agreement or any rights or obligations hereunder without the prior written consent of the other parties hereto and any such attempted assignment without such prior written consent shall be void and of no force and effect. This Agreement shall inure
to the benefit of and shall be binding upon the successors and permitted assigns of the parties hereto. Any corporation or association into which the Escrow Agent may be converted or merged, or with which it may be consolidated, or to which it may
sell or transfer all or substantially all of its corporate trust business and assets as a whole or substantially as a whole, or any corporation or association resulting from any such conversion, sale, merger, consolidation or transfer to which the
Escrow Agent is a party, shall be and become the successor escrow agent under this Agreement and shall have and succeed to the rights, powers, duties, immunities and privileges as its predecessor, without the execution or filing of any instrument or
paper or the performance any further act. 

  
 9 

 11.    Governing Law; Jurisdiction. This Agreement shall be construed,
performed, and enforced in accordance with, and governed by, the internal laws of the State of New York, without giving effect to the principles of conflicts of laws thereof. Each party hereby consents to the personal jurisdiction and venue of any
court of competent jurisdiction in the State of New York. 
 12.    Severability. If any part of this Agreement
is declared by any court or other judicial or administrative body to be null, void, or unenforceable, said provision shall survive to the extent it is not so declared, and all of the other provisions of this Agreement shall remain in full force and
effect. 
 13.    Amendments; Waivers. This Agreement may be amended or modified, and any of the terms,
covenants, representations, warranties, or conditions hereof may be waived, only by a written instrument executed by the parties hereto, or in the case of a waiver, by the party waiving compliance. Any waiver by any party of any condition, or of the
breach of any provision, term, covenant, representation, or warranty contained in this Agreement, in any one or more instances, shall not be deemed to be nor construed as further or continuing waiver of any such condition, or of the breach of any
other provision, term, covenant, representation, or warranty of this Agreement. The Company agrees that any requested waiver, modification or amendment of this Agreement shall be consistent with the terms of the Offering. 

14.    Entire Agreement. This Agreement contains the entire agreement and understanding among the parties hereto
with respect to the escrow contemplated hereby and supersedes and replaces all prior and contemporaneous agreements and understandings, oral or written, with regard to such escrow. 

15.    Section Headings. The section headings in this Agreement are for reference purposes only and shall not
affect the meaning or interpretation of this Agreement. 
 16.    Counterparts. This Agreement may be executed
(including by email or facsimile transmission) with counterpart signature pages or in counterparts, each of which shall be deemed an original, but all of which shall constitute the same instrument. 

17.    Resignation. The Escrow Agent may resign upon 30 days’ advance written notice to the Company. In the
event of any such resignation, a successor escrow agent, which shall be a bank or trust company organized under the laws of the United States of America, shall be appointed by the Company. Any such successor escrow agent shall deliver to the Company
a written instrument accepting such appointment, and thereupon shall succeed to all the rights and duties of the Escrow Agent hereunder and shall be entitled to receive the Subscriber Funds from the Escrow Agent. The Escrow Agent shall promptly pay
the Subscription Amounts in the Escrow Account, including interest thereon, to the successor escrow agent, whereupon the Escrow Agent’s obligations hereunder shall terminate. If a successor escrow agent is not appointed by the Company within
the 30-day period following such notice, the Escrow Agent may petition any court of competent jurisdiction to name a successor escrow agent, or may interplead the Subscriber Funds with such court, whereupon
the Escrow Agent’s duties hereunder shall terminate. 

  
 10 

 18.    Removal. The Escrow Agent may be removed by the Company at any
time by written notice provided to the Escrow Agent, which instrument shall become effective on the date specified in such written notice. The removal of the Escrow Agent shall not deprive the Escrow Agent of its compensation earned prior to such
removal. In the event of any such removal, a successor escrow agent, which shall be a bank or trust company organized under the laws of the United States of America, shall be appointed by the Company. Any such successor escrow agent shall deliver to
the Company a written instrument accepting such appointment, and thereupon shall succeed to all the rights and duties of the Escrow Agent hereunder and shall be entitled to receive the Subscriber Funds from the Escrow Agent. The Escrow Agent shall
promptly pay the Subscriber Funds in the Escrow Account, including interest thereon, to the successor escrow agent, whereupon the Escrow Agent’s obligations hereunder shall terminate. If a successor escrow agent is not appointed by the Company
within the 30-day period following such notice, the Escrow Agent may petition any court of competent jurisdiction to name a successor escrow agent, whereupon the Escrow Agent’s obligations hereunder shall
terminate. 
 19.    Maintenance of Records. The Escrow Agent shall maintain accurate records of all transactions
hereunder. Promptly after the termination of this Agreement, and as may from time to time be reasonably requested by the Company before such termination, the Escrow Agent shall provide the Company with a copy of such records, certified by the
Escrow Agent to be a complete and accurate account of all transactions hereunder. The authorized representatives of the Company shall also have access to the Escrow Agent’s books and records to the extent relating to its duties hereunder,
during normal business hours upon reasonable notice to the Escrow Agent. 
 20.    References to Escrow Agent.
Other than the Offering document (including the Registration Statement, Prospectus, the subscription agreement and respective exhibits thereto) and any amendments thereof or supplements thereto, no printed or other matter in any language (including,
without limitation, notices, reports and promotional material) which mentions the Escrow Agent’s name or the rights, powers, or duties of the Escrow Agent shall be issued by the Company, or on the Company’s behalf, unless the Escrow Agent
shall first have given its specific written consent thereto. 
 21.    Regulatory Compliance. The Company shall
provide to the Escrow Agent upon the execution of this Agreement any documentation or information reasonably requested by the Escrow Agent to comply with the USA Patriot Act of 2001, as amended from time to time, and the Bank Secrecy Act of 1970, as
amended from time to time. 
 22.    Electronic Transactions. The parties hereto agree that the transactions
described herein may be conducted and related documents may be stored by electronic means. Copies, telecopies, facsimiles, electronic files and other reproductions of original executed documents shall be deemed to be authentic and valid counterparts
of such original documents for all purposes, including the filing of any claim, action or suit in the appropriate court of law. 
 [signature
page follows] 

  
 11 

 IN WITNESS WHEREOF, the parties hereto have caused this Escrow Agreement to be executed the date
and year first set forth above. 
  

					
	Oaktree Real Estate Income Trust, Inc.
		
	By:	 	 /s/ Jordan Mikes

		 	Name:	 	Jordan Mikes
		 	Title:	 	Chief Securities Counsel and Secretary
		
	By:	 	 /s/ Brian Grefsrud

		 	Name:	 	Brian Grefsrud
		 	Title:	 	Chief Financial Officer and Treasurer
	
	UMB BANK, N.A., as Escrow Agent
		
	By:	 	 /s/ Timothy Cook

		 	Name:	 	Timothy Cook
		 	Title:	 	Senior Vice President

 Exhibit A 

LIST OF SUBSCRIBERS 
 Pursuant to the Escrow
Agreement dated April 26, 2018 by and between Oaktree Real Estate Income Trust, Inc. (the “Company”) and UMB Bank, N.A., as escrow agent (the “Escrow Agent”), the following investors have paid money for the
purchase of the Shares in the Company and the money has been deposited with the Escrow Agent: 
  

	1.	Name of Subscriber: 

 Address: 

Tax Identification Number: 

Amount and class of Securities subscribed for: 

Amount of money paid and deposited with Escrow Agent: 
  

	2.	Name of Subscriber: 

 Address: 

Tax Identification Number: 

Amount and class of Securities subscribed for: 

Amount of money paid and deposited with Escrow Agent:EX-10.14

 Exhibit 10.14 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 1
 of 27

  

 Commercial Supply Agreement 

This Commercial Supply Agreement (“Agreement”) is made and entered into as of May 14, 2018 (“Effective Date”) by and between PYRAMID
Laboratories Inc. (“PYRAMID”), a California Corporation, having its principal place of business at 3598 Cadillac Avenue, Costa Mesa, California 92626 and Xeris Pharmaceuticals, Inc. (“Client”), a Delaware corporation,
having its principal place of business at 180 N. LaSalle Street, Suite 1800, Chicago, Illinois, 60601, collectively the “Parties” and individually a “Party”. 

PURPOSE 
 Client is engaged in the
research, development and commercialization of pharmaceutical products; 
 PYRAMID is engaged in the business of providing product development and
commercial manufacturing services for pharmaceutical products; 
 PYRAMID and Client previously entered into a Master Service Agreement on November 1,
2016 (“Master Service Agreement”) to provide development services, produce clinical supplies, and produce commercial registration batches for pharmaceutical development programs, including products now defined as Commercial Product; 

NOW, THEREFORE, Client wishes to engage PYRAMID to perform the cGMP manufacturing Services for Commercial Product and PYRAMID wishes to provide such
manufacturing Services to Client, all in accordance with the terms and conditions of this Agreement; 
 NOW, THEREFORE, in consideration of the mutual
covenants and premises herein contained, the Parties hereto agree as follows: 
 AGREEMENT 

 

	1.	DEFINITIONS 

  

	 	1.1	“Active Pharmaceutical Ingredient” (“API”) means Glucagon Pharmaceutical Grade material as supplied by Client. 

 

	 	1.2	“Affiliates” means any corporation, firm, partnership or other entity which directly or indirectly controls, is controlled by, or is under common control of a Party to this Agreement. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 2
 of 27

  

	 	1.3	“Client Materials” means any Active Pharmaceutical Ingredients, equipment, or primary container components supplied to PYRAMID by Client for testing or manufacture of Commercial Product under any Firm
Order or Purchase Order. Client Materials are listed in Schedule B. 

  

	 	1.4	“Commercial Product” means the products listed in Schedule C. 

  

	 	1.5	“Firm Order” has the meaning specified Section 3.2. 

  

	 	1.6	“FDA” means the United States Food and Drug Administration. 

  

	 	1.7	“cGMP” means the current Good Manufacturing Practices for manufacturing finished pharmaceutical products as set forth in 21 CFR Parts 210 and 211, the guidelines to GMP (under European directive
2003/94/EC) or any foreign equivalent specified in the applicable Firm Order or Purchase Order. 

  

	 	1.8	“Batch” means a specific quantity of manufactured Commercial Product, or a specific identified portion thereof (each a specific batch or sub-lot), having uniform
characteristics and quality within limits as defined in the Specifications (and as set forth in 21 CFR Part 211). 

  

	 	1.9	“Purchase Order” means an order for Commercial Product pursuant to the terms of this Agreement and the Quality Agreement, and as defined in Section 3.2. 

 

	 	1.10	“Quality Agreement” means the Quality Agreement between the Parties dated November 16, 2016, and as may be further amended from time to time, which contains current Commercial Product
Specifications and specifies Parties’ respective responsibilities regarding the manufacture, packaging, testing, storage, release, quality control, quality assurance and shipment of Commercial Product in accordance with requirements of
Regulatory Standards and cGMP’s. In the event that any conflict shall arise between the terms of this Agreement and the Quality Agreement, the terms of this Agreement shall take precedence over the terms of the Quality Agreement in all respects
except matters of quality, regulatory affairs and pharmacovigilance, in which case the Quality Agreement shall take precedence. 

  

	 	1.11	“Regulatory Standards” means requirements of the FDA or any foreign equivalent requirements for PYRAMID’s facility, cGMP and all other regulations applicable to PYRAMID, PYRAMID’s facility,
and PYRAMID’s manufacture, packaging, testing, quality control, quality assurance and shipment of Commercial Product. 

  

	 	1.12	“Services” has the meaning defined in Section 2. 

  

	 	1.13	“Specifications” means: 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 3
 of 27

  

	 	(a)	the file, for the Commercial Product, which is provided by Client to PYRAMID and which contains documents related to such Commercial Product, including, without limitation: 

(1) written Specifications for Active Pharmaceutical Ingredient, primary container components, PYRAMID supplied materials and consumables, and
finished Commercial Product; 
 (2) manufacturing, process control, packaging and labeling Specifications; 

(3) shipping and storage requirements; 

(4) all environmental, health and safety information relating to Client Materials and Commercial Product including materials safety data
sheets, all as updated, amended and revised from time to time by Client in accordance with the terms of the Agreement; and 
 (5) any other
technical information necessary to carry out the contracted operations correctly in accordance with any legal requirements. 
  

	 	1.15	“Contract Year” means the twelve (12) month period commencing, in the case of the first year of this Agreement, on the Effective Date, and thereafter commencing on the twelve (12) month
anniversary date in subsequent years. 

  

	 	1.16	“Calendar Year” means in the case of the first year of this Agreement, the Effective Date through December 31st of the same year, and thereafter
January 1 through December 31st in subsequent years. 

  

	 	1.17	“Validation Batch” means a Batch that requires testing and documentation beyond what is required per this Agreement. 

 

	 	1.18	“Intellectual Property” means any and all of the following in any jurisdiction throughout the world: (i) trademarks, trade dress, trade names and service marks, including all applications and
registrations therefor and the goodwill connected with the use of and symbolized by the foregoing; (ii) works of authorship and copyrights, including all applications and registrations related to the foregoing; (iii) trade secrets,
proprietary information, inventions and confidential know-how; (iv) patents and patent applications; (v) internet domain name registrations, social media and other identifiers of source; and
(vi) other intellectual property and related proprietary rights, interests and protections. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 4
 of 27

  

	2.	SCOPE OF AGREEMENT 

 Under this Agreement, Client may request PYRAMID to
manufacture, fill, package, label, store, and test Commercial Product from time to time (“Services”). PYRAMID shall: 
  

	 	2.1	Ensure that all manufacturing under this Agreement shall be in accordance with the Specifications, the Quality Agreement, Regulatory Standards, cGMP’s and a Purchase Order. 

 

	 	2.2	PYRAMID shall perform quality control and quality assurance testing in accordance with the protocols specified in the Specifications and Quality Agreement. PYRAMID shall not make any changes to such testing protocols
without the prior written approval from Client. In the event that any Batch of Commercial Product fails test Specifications, PYRAMID and Client, in accordance with the Quality Agreement, shall jointly determine the proceedings and methods to be
undertaken to investigate the causes of such failure, including which Party shall bear the cost of such investigation, provided that PYRAMID shall not be liable for any such costs unless there has been a failure by PYRAMID to provide the Services in
accordance with this Agreement or the Quality Agreement. PYRAMID will provide any and all data and results relating to the testing upon request by Client. 

  

	 	2.3	PYRAMID shall receive and perform identity testing of all materials, including PYRAMID supplies, materials and consumables and Client Materials, including the Active Pharmaceutical Ingredient, necessary for
manufacturing or as otherwise specified in the Quality Agreement and as necessary to meet cGMP requirements. 

  

	 	2.4	Client shall supply all of the items listed in Schedule B to PYRAMID and Client shall be solely responsible for all costs and expenses relating thereto. Client shall be responsible for ensuring that Client Materials
listed in Schedule B are ordered in sufficient quantities and delivered to PYRAMID in sufficient time to enable PYRAMID to meet Rolling Forecast and Firm Order requirements of Client. Client Materials, including the Active Pharmaceutical Ingredient,
shall at all times belong to and remain the property of Client. PYRAMID agrees that Client Materials received by PYRAMID shall only be used to provide Services for the Client. Any excess Client Materials shall be returned to Client or destroyed, at
Client’s expense, upon request and/or upon expiration or termination of this Agreement. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 5
 of 27

  

	3.	ORDERING 

  

	 	3.1	Forecasts 

  

	 	3.1.1.	Prior to the end of each month, beginning approximately [***] prior to the expected FDA approval date for a Commercial Product, Client shall provide a written [***] forecast of the volume for each Commercial Product
that Client anticipates will be required to be produced and delivered to Client (or designee) during the following [***] (“Rolling Forecast”). Rolling Forecasts will be updated by Client at the end of each subsequent month and PYRAMID
shall inform Client within [***] of receiving an updated forecast if a Rolling Forecast cannot be met or is at risk of not being met. Failure of PYRAMID to accept or reject a Rolling Forecast within [***] of receipt shall be deemed an acceptance of
the forecast and confirmation of having suitable available capacity for [***] of the Rolling Forecast. 

  

	 	3.1.2.	At the beginning of each Calendar Year, Client shall provide a written [***] forecast for each Commercial Product (“Long Term Forecast”). PYRAMID shall review the Long-Term Forecast within [***] and provide a
written commitment of total production capacity available for Commercial Product for the following [***] period (“Total Capacity Commitment”). Failure of PYRAMID to accept or reject a Long-Term Forecast within [***] of receipt shall be
deemed as making a Total Capacity Commitment for [***] of the Long-Term Forecast. If Client’s Long-Term Forecast cannot be manufactured due to PYRAMID’s limitations of the Total Capacity Commitment, Parties agree in good faith to evaluate
and agree to alternative solutions, provided however, Client shall have the option of [***] as provided for under Section 24. 

  

	 	3.2	Orders 

  

	 	3.2.1	On or before the last day of each month, Client shall provide firm written orders for Commercial Product to PYRAMID, and such orders shall specify the amount of Commercial Product that shall be produced by PYRAMID and
delivered to Client on a date not less than [***] from the first day of the following month (each a “Firm Order”). Firm Orders shall be submitted to PYRAMID in the form of individual or multiple Purchase Orders and shall specify
Client’s Purchase Order number, quantities for each Commercial Product, delivery schedule, and any other elements necessary to ensure the timely production and delivery of the Commercial Product (each a “Purchase Order”). Purchase
Orders for Commercial Products shall be firm and binding on Client except as otherwise provided for in Sections 3.2.4 and 3.2.5. 

  

	 	3.2.2	Each batch of Commercial Product shall have an expected output based on manufacturing scale and yield (“Target Batch Yield”), as further defined in Schedule A, and may only submit Purchase Orders for
Commercial Product in multiples of the Target Batch Yield. At the beginning of each Calendar Year, Parties agree to review and revise Target Batch Yield for Commercial Products, as necessary, based on updated production history. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 6
 of 27

  

	 	3.2.3	PYRAMID shall inform Client within [***] in writing or by email if a Purchase Order cannot be filled and delivered as requested. Failure of PYRAMID to accept or reject a Purchase Order within [***] of receipt shall be
deemed an acceptance of the Purchase Order. 

  

	 	3.2.4	[***]. 

  

	 	3.2.5	Client shall not be allowed to adjust or cancel a Purchase Order [***] unless Parties mutually agree to utilize manufacturing time allocated for the Purchase Order for another Commercial Product or comparable Client
special project under the Master Service Agreement. 

  

	 	3.2.6	Client Materials must be received by PYRAMID at least [***] in advance of scheduled Purchase Order manufacturing in order to reserve necessary PYRAMID resources and manufacturing time. 

 

	 	3.2.7	Each Batch under a Purchase Order delivered more than [***] beyond the delivery date specified in a Purchase Order shall be considered a Late Delivery (“Late Delivery”) and PYRAMID shall incur a penalty as
further defined in Section 7.2. For clarity, Late Deliveries due to (a) Client’s failure to supply Client Materials in advance of scheduled manufacturing, or (b) quality issues related to such Client Materials, or
(c) changes agreed upon in Sections 3.2.4 and 3.2.5 shall not be considered a Late Delivery. 

  

	 	3.3	Pricing 

  

	 	3.3.1	At the beginning of each Calendar Year, based on the quantity of Commercial Product forecasted by Client in the most recent Rolling Forecast for that Calendar Year, Parties agree to select and apply the appropriate
pricing schedule as defined in Schedule A. The selected pricing schedule shall apply to all Client’s Purchase Orders scheduled for delivery during that Calendar Year, including Purchase Orders previously created and scheduled for delivery in
that Calendar Year, and for which pricing shall be adjusted accordingly as required. 

  

	 	3.3.2	Parties agree that prices set forth in Schedule A shall be updated [***]. 

  

	 	3.3.3	Parties agree that since Validation Batches require additional documentation and testing, pricing for any such Validation Batches shall be [***] compared to the then applicable Commercial Product Purchase Order price.
PYRAMID will produce a Validation Batch only upon the written request of Client submitted in a Purchase Order. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 7
 of 27

  

	 	3.3.4	At the end of each Calendar Year, based on the actual quantity of Commercial Product ordered by Client, defined as all Purchase Orders scheduled for delivery in that Calendar Year, Parties agree to review annual
purchase volume to determine if a different pricing schedule should have been applied for the past full Calendar Year. As a result of the review and reconciliation process, and if required, PYRAMID shall issue a credit to Client for any amount due
and apply it to the following years purchases, or Client shall pay PYRAMID for any amount due [***] of completing the year end reconciliation process. 

  

	4.	MANUFACTURING 

  

	 	4.1	PYRAMID will manufacture, package and label Batches for Purchase Orders in accordance with Section 2 of this Agreement, Commercial Product Specifications, the Quality Agreement and cGMP’s. 

 

	 	4.2	PYRAMID shall test Batches and deliver Batch documentation for each Purchase Order to Client in accordance with the Quality Agreement, and such Batch documentation shall be delivered to Client at least [***] prior to
the delivery date specified on each Purchase Order. 

  

	 	4.3	If the yield of a Batch is [***] below the Target Batch Yield as defined in Schedule A, Parties agree to investigate the root cause for the lower yield in accordance with the Quality Agreement. If the cause of the lower
than expected yield is due to operator error or gross negligence by PYRAMID, PYRAMID may be subject to a penalty as further defined in Section 7.2. 

  

	 	4.4	PYRAMID shall replace any Batch that does not meet Specifications and is due to PYRAMID failure [***] and as soon as reasonably possible, and PYRAMID shall [***] as defined in Section 7.2.5. For clarity, any Batch
rejection due to a failure of Client Materials shall not result in a PYRAMID liability as provided for herein and Parties shall work together at Client’s cost to replace the Batch as soon as reasonably possible. 

 

	 	4.5	Services related to Commercial Product that are outside of routine commercial manufacturing and supply as defined within this Agreement shall be managed separately as special projects and in accordance with the Master
Service Agreement. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 8
 of 27

  

	5.	SPECIFICATIONS 

 Specifications for Commercial Product and any proposed revision to such
Specifications shall be managed in accordance with the Quality Agreement. Revisions to Specifications requested by either Party will only be implemented following a technical review and cost assessment by PYRAMID and are subject to Client and
PYRAMID reaching agreement as to pricing revisions in Schedule A, if necessitated by any such revision. If Client accepts a proposed price change, the proposed revision to the Specifications shall be implemented in accordance with the Quality
Agreement, and the price change shall become effective only with respect to those Purchase Orders that are manufactured in accordance with the revised Specifications. If Parties cannot agree on a proposed price revision, Client shall have the right
to terminate the Agreement in accordance with Section 24. 
  

	6.	SHIPPING 

  

	 	6.1	PYRAMID will prepare and ship Quality Control samples for Commercial Product to a laboratory designated by Client for testing, as required, in accordance with the Specifications and Quality Agreement. 

 

	 	6.2	Once a Commercial Product Batch is fully tested and released in accordance with Sections 4.2 and 9, the Specifications and the Quality Agreement, Client will arrange for pick up and shipment of the Commercial Product in
accordance with the Specifications and Purchase Order. Client shall be responsible for payment of freight, insurance, customs duties and related charges for delivery of packaged Commercial Product to Client or alternate recipient as designated by
Client, unless otherwise specified in the Purchase Order. 

  

	7.	INVOICING, PAYMENT, ADJUSTMENTS  

  

	 	7.1	Invoicing and Payment  

  

	 	7.1.1	

  

	 	7.1.1	Purchase Orders may require a down payment as defined in Schedule A. PYRAMID shall invoice Client for any such down payment upon receipt of a signed Purchase Order and payment of such invoice are due [***] after receipt
by Client. 

  

	 	7.1.2	PYRAMID shall invoice Client for a Purchase Order after Batch documentation, including a Certificate of Analysis with successful sterility and endotoxin test results, has been delivered to Client in accordance with the
Quality Agreement. Each invoice shall identify the Purchase Order number, Client part number, Commercial Product name, quantity delivered, unit price, freight charges and the total amount to be paid by Client. Undisputed invoices are due within
[***] after receipt by Client. 

  

	 	7.1.3	Client agrees to pay PYRAMID for production costs associated with cancelled Firm Orders. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 9
 of 27

  

	 	7.1.4	All late payments shall bear interest at a rate of [***], if not prohibited by law, otherwise at the highest lawful contract rate. 

  

	 	7.1.5	Except as otherwise provided in the applicable Purchase Order, Client will pay to PYRAMID any federal, state and local sales taxes, if applicable, based on or measured by the sale or use of packaged Products, exclusive
of any taxes based on PYRAMID’s income, revenues, gross receipts, personnel, or real or personal property, or other assets. 

  

	 	7.2	Invoice Adjustments 

  

	 	7.2.1	For any firm Purchase Order revised by Client [***] unless Parties mutually agreed to utilize manufacturing time scheduled for the Purchase Order for another purpose, as further defined under Section 3.2.5.

  

	 	7.2.2	For any Batch that is cancelled by Client, and that is associated with a firm Purchase Order, Client shall pay PYRAMID [***] and Client shall have no further obligations for the Purchase Order. 

 

	 	7.2.3	For any Late Delivery of a Batch under a Purchase Order as further defined in Section 3.2.7, PYRAMID shall incur a penalty of [***]. 

 

	 	7.2.4	For any Batch manufactured with a yield of [***] due to PYRAMID operator error or gross negligence as further defined in Section 4.3, Client shall have the option [***] subject to limitations defined under
Section 22. 

  

	 	7.2.5	PYRAMID shall be responsible for the replacement cost of any Batch that does not meet Specifications and is not delivered to Client as further described in Section 4.4, [***] subject to limitations defined under
Section 22. 

  

	 	7.3	Defaults in Payment 

 In the event of default in the payment for Services rendered or
expenses incurred by PYRAMID for Client, pursuant to this Agreement, Client shall be responsible for all collection fees and expenses incurred by PYRAMID, including attorneys’ fees. In the event of default in the reimbursement for Service fees
or Client Materials to Client by PYRAMID, pursuant to this Agreement, PYRAMID shall be responsible for all collection fees and expenses incurred by Client, including attorneys’ fees. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 10
 of 27

  

	8.	CLIENT MATERIALS AND PRODUCT 

  

	 	8.1	Client Materials will remain Client’s property at all times and will only be used by PYRAMID for the purposes of manufacturing Commercial Product in accordance with this Agreement. 

 

	 	8.2	PYRAMID must store and maintain Client Materials in such a way that they are clearly identifiable as Client’s property and in accordance with the Quality Agreement and cGMP. 

 

	 	8.3	Client Materials will be insured by Client against any damages that may occur during the storage at the premises of PYRAMID. PYRAMID will not be liable for destruction or deterioration of these materials unless
destruction or deterioration is due to the negligence or willful misconduct on the part of PYRAMID, and in such case of negligence or willful misconduct, PYRAMID will be insured to cover property loss and limits as further described in
Section 21 and 22. 

  

	 	8.4	Client shall provide to PYRAMID the most current technical data relating to the Commercial Product and Client Materials, including, but not limited to, Specifications, material data safety sheets, and pertinent
environmental health and safety information, necessary to assure safe handling and disposal of the Commercial Product and the Client Materials by PYRAMID employees. 

 

	 	8.5	PYRAMID will provide to Client a monthly inventory report within [***] after the end of each month. The report will include Client Materials, in process Commercial Product, and finished Commercial Product stored or
pending release and shipment, and shall include part number, material description, quantity, lot number, expiration date and material disposition. Parties agree to use best efforts to investigate and reconcile any discrepancies within [***] of
Client receiving such inventory report. 

  

	9	QUALITY ASSURANCE 

 The Quality Agreement, as defined in Section 1, forms an
integrated part of this Agreement and describes in detail cGMP, quality control and quality assurance responsibilities of each Party. The Quality Agreement includes, but is not limited to, technical and quality contact information, roles and
responsibilities, facility and equipment requirements, Commercial Product Specifications, material and vendor management, manufacturing qualification and validation, in-process testing and control, rework or
reprocessing, packaging and labeling, analytical testing methods, Batch disposition and documentation, and storage and transportation. The Quality Agreement shall also address the use of subcontractors, specific regulatory and country reporting
requirements, change control, deviation and nonconforming product investigations, corrective and preventative actions, and dispute resolution. In the event that any conflict shall arise between the terms of this Agreement and the Quality Agreement,
the terms of the Quality Agreement shall take precedence over the terms of this Agreement in all respects related to quality, regulatory affairs and pharmacovigilance. Parties agree to review the Quality Agreement within [***] of the Execution Date,
and update the Quality Agreement as necessary, to reflect this Agreement and related requirements. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 11
 of 27

  

	10.	REGULATORY INSPECTIONS 

 PYRAMID’s obligations to notify and cooperate with Client
regarding any audit or inspection by a competent regulatory authority with respect to the manufacture or testing of Products will be as set out in the Quality Agreement. All costs associated with PYRAMID’s compliance or support with
(a) any official requests for information or documents relating to Services performed or Commercial Products provided by PYRAMID to Client exclusively under this Agreement, or (b) Client Commercial Product regulatory submission, or
(c) regulatory authority audits exclusively related to Commercial Product, shall be paid by Client. Client shall reimburse PYRAMID for all such costs including, but not limited to, an hourly charge of [***] for persons responding to requests,
travel, lodging, meals, mileage, incidental expenses, reasonable attorneys’ fees for preparation of any person called to testify and associated fees and all other reasonable expenses associated with any such requests. 

 

	11.	SITE VISITS 

  

	 	11.1	In accordance with the Quality Agreement, Client may conduct Quality Assurance Site Compliance Audits each calendar year on a date mutually agreed upon by the Parties. The first (1st) day will be at no charge to Client and additional days will be charged at [***]. The Quality Assurance Site Compliance Audit includes the right to inspect any facility being used by PYRAMID for the
Services and to inspect all relevant records. Any additional audits specific to Commercial Product, including those by FDA or a Qualified Person, will be charged at [***]. 

 

	 	11.2	If Client is conducting a for cause audit or Parties agree that a major non-conformance is found and requires resolution and meetings necessary to verify corrective action has
been taken as provided for in the Quality Agreement, such activity will not result in a daily audit charge to Client. 

  

	 	11.3	In accordance with the Quality Agreement, Client may conduct a preparatory audit of PYRAMID in advance of an expected pre-approval inspection by a Regulatory Authority at no
charge to the Client. 

  

	 	11.4	PYRAMID will co-operate fully with Client during audits performed under this section, including furnishing to Client copies of all requested documents. 

 

	 	11.5	PYRAMID will provide to Client access to PYRAMID’s facilities at no charge during execution of manufacturing Services under any Purchase Order, upon reasonable notice, for the purpose of providing technical
assistance or observing performance of the Services. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 12
 of 27

  

	12.	RECORDS 

  

	 	12.1	Unless stated otherwise in the Quality Agreement or Specifications, PYRAMID will, at its own expense, store all testing and quality control records relating to Commercial Products onsite for [***]; and for a period of
[***] offsite following completion of production of the Commercial Product. At the end of the [***], Client shall be notified to determine whether the records may be destroyed, provided to Client or continue to be stored at Client’s request or
expense. 

  

	 	12.2	PYRAMID will maintain, in accordance with Generally Accepted Accounting Principles and Practices, records reflecting the accuracy of PYRAMID’s charges, including invoices for compensation, and other information as
Client may reasonably require in connection with this Agreement (“Financial Records”). PYRAMID will preserve such documents, without receipt of additional compensation, for at least [***] after the date of the final payment.

  

	13.	PRODUCT REJECTION, RECALLS, ADVERSE EVENTS 

  

	 	13.1	In accordance with the Quality Agreement, Client will have the right to reject any Commercial Product Batch that has not been manufactured in compliance with PYRAMID’s warranty in Section 17 or does not meet
the established Specifications. 

  

	 	13.2	Client’s right of rejection will be exercised by delivery of written notice to PYRAMID in accordance with the procedures set out in the Quality Agreement or within [***] of receiving final Batch release
documentation, including a Certificate of Analysis, or in the case of Latent Defects due to a PYRAMID processing failure, shall be upon Client’s discovery any time during the shelf-life of the Commercial Product. For the purposes of this
Agreement, “Latent Defect” means a hidden flaw, weakness or imperfection of the Commercial Product unrelated to Client Materials which cannot be readily ascertained from the mere observation or a reasonable or customary inspection of the
such product and the root cause for any such Latent Defect must be proven or detected through product investigation. Any quantities of Commercial Product that are rejected pursuant to this section will be returned to PYRAMID at PYRAMID’s
expense, and either [***]. For the avoidance of doubt, PYRAMID shall not be liable for Latent Defects related to Client Materials. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 13
 of 27

  

	 	13.3	In accordance with the Quality Agreement, if PYRAMID disputes Client’s basis for rejecting a Commercial Product, then PYRAMID must do so in writing within [***] of receiving a rejection notice from Client. The
rejected Commercial Product will be tested by an independent GMP laboratory mutually agreed upon by the Parties and the independent laboratory’s determination will be final and binding on the Parties. The cost of such testing will be borne by
PYRAMID if the independent laboratory confirms that the product in question does not comply with PYRAMID’s warranty or other limitations, as provided for in Sections 17 and 22. Otherwise, the costs will be borne by Client. 

 

	 	13.4	In accordance with the Quality Agreement, Parties shall work collaboratively in a timely manner to initiate and process Recalls related to Commercial Product. If the cause of the Recall is related to PYRAMID’s
failure to comply with PYRAMID’s warranty in Section 17 or other provisions of this Agreement, PYRAMID shall reimburse Client for the cost of the Services and Client Materials used to manufacture the Commercial Product involved in the
Recall along with reasonable and documented Recall expenses, subject to limitations provided for in Section 22. 

  

	 	13.5	In accordance with the Quality Agreement, Parties shall work collaboratively in a timely manner to report and investigate Adverse Events and Product Complaints related to Commercial Product. 

 

	14.	INTELLECTUAL PROPERTY 

  

	 	14.1	Client will retain ownership of any Intellectual Property in the Specifications, Commercial Product formulation, Commercial Product manufacturing processes and Client Materials. Except for the limited purpose of
performing its obligations under this Agreement, PYRAMID is not granted any right, title or interest in any intellectual property owned or controlled by Client. 

  

	 	14.2	All right, title and interest in and to Intellectual Property produced, created, invented or developed by PYRAMID, including without limitation any improvements or modifications to the Client Materials, in performance
of formulation development, analytical testing and/or the manufacture of Commercial Product under a Purchase Order (all of the foregoing, “Developed IP”) will be considered a
work-made-for-hire and belong to and owned by Client. To the extent such Developed IP is not a
work-made-for-hire under the applicable law, PYRAMID does assign and will assign all rights, title, and interest in and to such Developed IP to Client. PYRAMID agrees to
reasonably cooperate and to complete, at Client’s expense, any documents necessary for Client to file and prosecute applications for registration of such Developed IP, including filing and prosecuting patent applications with respect to such
Developed IP, in Client’s name. PYRAMID will, if deemed necessary or desirable by Client, on the same terms, execute an assignment of rights to Client with respect to such Developed IP, including any patent applications or patents.

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 14
 of 27

  

	15.	CONFIDENTIALITY 

  

	 	15.1	For purposes of this Agreement, the term “Information” will mean: 

  

	 	(a)	With respect to Client, the Specifications, assigned intellectual property, information relating to the Commercial Products and Client Materials and their manufacture including such information produced by PYRAMID in
performance of any Purchase Order, all written information which Client delivers to PYRAMID pursuant to this Agreement stamped or otherwise identified in writing on the document “Confidential,” and all oral information which Client
declares to be confidential and confirms such declaration in writing within [***] of disclosure; and 

  

	 	(b)	With respect to PYRAMID, all information relating to PYRAMID’s manufacturing procedures, techniques and/or facilities, which PYRAMID delivers to Client in performance of monitoring or auditing under this Agreement
stamped or otherwise identified in writing on the document “Confidential” if in writing, or if disclosed verbally, PYRAMID declares to be confidential and confirms such declaration in writing within [***] of disclosure. 

 

	 	15.2	A Party receiving Information (“Receiving Party”) from the other Party (“Disclosing Party”) will maintain the Information in confidence with the same degree of care it holds its own confidential
information. The Receiving Party will only use the Information for the purposes of performing its obligations or exercising its rights under this Agreement. The Receiving Party will not disclose the Information to any third party and will only
disclose the Information to its officers and employees that need the Information for the purposes of performing its obligations or exercising its rights under this Agreement. 

 

	 	15.3	The Receiving Party’s obligation of nondisclosure and the limitations upon the right to use the Information shall not apply to the extent that the Receiving Party can demonstrate that the Information:

  

	 	(a)	was in the possession of the Receiving Party prior to the time of disclosure; or 

  

	 	(b)	is or becomes public knowledge through no fault or omission of Receiving Party; or 

  

	 	(c)	is obtained by Receiving Party from a third party under no obligation of confidentiality to the Disclosing Party. All Information will be returned to the Receiving Party upon termination of this Agreement for any
reason, except for one copy, which Disclosing Party may use for the sole purpose of determining its continuing confidentiality obligation to the Disclosing Party under this Agreement; or 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 15
 of 27

  

	 	(d)	if the Receiving Party is requested or ordered to disclose the Information in connection with a legal or administrative proceeding, the Receiving Party will give the Disclosing Party prompt notice of such request. The
Disclosing Party may seek an appropriate protective order or other remedy or waive compliance with the provisions of this Agreement or both. If the Disclosing Party seeks a protective order or other remedy, the Receiving Party will cooperate with
the Disclosing Party. If the Disclosing Party fails to obtain a protective order or waive compliance within the relevant provisions of this Agreement, the Receiving Party will disclose only that portion of Information which its legal counsel
determines it is required to disclose. 

  

	 	15.4	All information will be returned to the Receiving Party upon termination of this Agreement for any reason, except for one copy, which may be retained by the Receiving Party’s legal counsel for the sole purpose of
determining the Receiving Party’s continuing confidentiality obligation to the Disclosing Party under this agreement. 

  

	 	15.5	All confidentiality obligations of under this Agreement will survive the expiration or termination of this Agreement for a period of [***].  

 

	16.	RELATIONSHIP  

  

	 	16.1	PYRAMID is an independent contractor and PYRAMID acknowledges that its personnel or employees are not employees of Client. Accordingly, neither PYRAMID nor its employees or personnel will (a) participate in Client
employee benefit plans nor receive any other compensation beyond that stated above, (b) have the power or authority to bind Client or to assume or create any obligation or responsibility, express or implied, on Client’s part or in
Client’s name, except as otherwise set forth in this Agreement, or (c) represent to any person or entity that PYRAMID, its personnel or any employee of PYRAMID has such power or authority. PYRAMID will remain solely liable for all aspects
of the employment of such persons including, without limitation, recruitment, hiring, firing, training, promotion, compensation, all payroll taxes and other deductions and all premiums or payments made for workers’ compensation coverage,
unemployment benefits or any other payments required by law to be made by employers for or on behalf of employees. 

  

	 	16.2	PYRAMID represents and warrants that it and its personnel, and employees are authorized to perform the Services and that neither it nor its personnel or employees will act in violation of any applicable immigration laws
or regulations. PYRAMID will indemnify Client against any and all claims, fines, penalties and/or attorneys’ fees incurred by Client for breach by PYRAMID of any immigration laws or regulations and of this warranty. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 16
 of 27

  

	17.	PYRAMID WARRANTIES 

 PYRAMID represents warrants and covenants that: 

 

	 	17.1	all Commercial Product supplied to Client under this Agreement will be manufactured in accordance with cGMP’s, Specifications and Regulatory Standards, and otherwise comply with the obligations set forth in
Section 2 above, and all Client Materials, PYRAMID supplied materials and consumables, in-process Commercial Product and finished and packaged Commercial Product shall be stored, processed, and shipped in
accordance with cGMP’s, Specifications and Regulatory Standards. 

  

	 	17.2	it is a corporation duly organized and existing in good standing under the laws of the state of its incorporation; 

  

	 	17.3	it has the right and authority to enter into and perform its obligations under this Agreement; 

  

	 	17.4	it will perform all of its obligations under this Agreement in accordance with all applicable governmental laws, rules and regulations; 

 

	 	17.5	it and its employees, affiliates, and agents have never been debarred, or convicted of a crime for which a person can be debarred (i) under Section 306(a) or (b) of the Generic Drug Enforcement Act of
1992, or (ii) for the award of United States of America Federal contracts; and none of PYRAMID’s employees, affiliates, or agents, according to PYRAMID’s best knowledge after due inquiry, has ever been threatened to be debarred or
indicted for a crime or otherwise engaged in conduct for which a person can be debarred, (i) under Section 306(a) or (b), or (ii) for the award of United States of America Federal contracts . PYRAMID agrees that it will promptly
notify Client upon learning of any such debarment, conviction, threat or indictment; and 

  

	 	17.6	the foregoing warranty is made to Client only and is not transferable to any agents or assigns of Client except to permitted assigns as described in Section 25.1. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THESE
TERMS AND CONDITIONS, PYRAMID MAKES NO REPRESENTATION AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 

 

	18.	CLIENT WARRANTIES 

 Client represents, warrants, and covenants that: 

 

	 	18.1	it is a corporation duly organized and existing in good standing under the laws of the state of its incorporation; 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 17
 of 27

  

	 	18.2	the Commercial Product and PYRAMID’s use of the processes or procedures described in the Specifications will not infringe the intellectual property rights of third parties; 

 

	 	18.3	it has the right and authority to enter into and perform its obligations under this Agreement; and 

  

	 	18.4	it will perform all of its obligations under this Agreement in accordance with all applicable governmental laws, rules and regulations. 

 

	19.	INDEMNIFICATION BY PYRAMID 

  

	 	19.1	PYRAMID will defend, indemnify and hold harmless Client and its Affiliates, and its or their officers, directors, shareholders, employees, agents and representatives from and against any and all liability, damage, loss,
cost or expense (including reasonable attorney’s fees, costs and amounts paid in settlement) (collectively, “Losses”) resulting from any third party claim made or suit brought against Client or any such persons arising out of
(a) PYRAMID’s breach of any of its representations, warranties or covenants in Section 17; (b) the use by Client of any Commercial Product or Special Product supplied by PYRAMID under this Agreement that does not comply with its
applicable Specifications, or (c) infringement of any third party Intellectual Property to the extent such infringement is not caused by or attributable to Client Materials. 

 

	 	19.2	Upon receipt of notice of any such claim or suit, Client will promptly notify PYRAMID thereof and will permit PYRAMID, at its cost, to handle and control such claim or suit; provided, however, that PYRAMID may not
settle or compromise any claim or consent to the entry of any judgment regarding which indemnification is being sought hereunder without Client’s prior written consent. Client will have the right to participate in the defense of such claim or
suit at its own expense. Client shall afford PYRAMID all reasonable assistance (at PYRAMID’s cost and expense) and will make no admission prejudicial to the defense of such claim or suit. 

 

	 	19.3	The foregoing indemnification obligation will not apply to any claim or suit to the extent it arises directly out of Client’s negligence, willful misconduct or breach of any term, representation, warranty or
covenant contained in this Agreement. 

  

	20.	INDEMNIFICATION BY CLIENT 

  

	 	20.1	Client will defend, indemnify and hold harmless PYRAMID and its Affiliates, and its or their officers, directors, shareholders, employees, agents and representatives from and against any and all liability, damage, loss,
cost or expense (including reasonable attorney’s fees, costs and amounts paid in settlement) (collectively, “Losses”) resulting from any third party claim made or suit brought against PYRAMID or any such persons arising out of
(a) Client’s breach of any of its representations, warranties or covenants in Section 18; (b) the use by Client of any Commercial Product or Special Product supplied by PYRAMID under this Agreement that complies with its applicable
Specifications, or (c) infringement of any third party Intellectual Property to the extent such infringement is caused by or attributable to Client Materials. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 18
 of 27

  

	 	20.2	Upon receipt of notice of any such claim or suit, PYRAMID will promptly notify Client thereof and will permit Client, at its cost, to handle and control such claim or suit. PYRAMID will have the right to participate in
the defense of such claim or suit at its own expense. PYRAMID will afford Client all reasonable assistance (at Client’s cost and expense) and will make no admission prejudicial to the defense of such claim or suit. 

 

	 	20.3	The foregoing indemnification obligation will not apply to any claim or suit to the extent it arises directly out of PYRAMID’s negligence, willful misconduct or breach of any term, representation, warranty or
covenant contained in this Agreement. 

  

	21.	INSURANCE 

 At all times commencing with the Effective Date of the signed Agreement,
Client shall maintain adequate product or general liability insurance and shall maintain adequate property insurance to appropriately cover the replacement cost of Client Materials. At all times commencing with the Effective Date of the signed
Agreement, PYRAMID shall carry insurance adequate to cover its interest or liabilities hereunder including, but not limited to, worker’s compensation, general liability, and property insurance sufficient to cover damage to Pyramid materials and
Client Materials, as further defined in Section 8.3 and such coverage shall be a [***]. 
  

	22.	LIMITATION OF LIABILITY 

 Except for breach of the Confidentiality Obligations, or
liability for infringement or misappropriation of their party Intellectual Property rights, each Party’s liability under this Agreement shall be [***]. Neither Party shall be liable under this Agreement, whether in tort, contract or otherwise,
for any indirect, incidental or consequential losses or any punitive or exemplary damages. 
  

	23.	PUBLICITY 

  

	 	23.1	No press releases or other statements in connection with this Agreement intended for use in the public or private media shall be made by Client or PYRAMID without the prior written consent of the other Party. If either
Party is required by law or governmental regulation to describe its relationship to the other, it will promptly give the other Party notice with a copy of any disclosure it proposes to make. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 19
 of 27

  

	 	23.2	In addition, PYRAMID will not use Client’s name in connection with any products, services, promotion, or advertising without Client’s prior written permission. 

 

	24.	TERM AND TERMINATION 

  

	 	24.1	This Agreement will end on completion of the Services set forth herein or under the last Purchase Order placed within five (5) years from the Effective Date. This Agreement shall automatically continue after the
Initial Term for successive terms of two (2) years each unless either Party gives written notice to the other Party of its intention to terminate this agreement giving twenty-four (24) months’ notice. 

 

	 	24.2	Either Party at its sole option may immediately terminate this Agreement upon written notice, but without prior advance notice, to the other Party in the event that (i) the other Party is declared insolvent or
bankrupt by a court of competent jurisdiction; (ii) a voluntary petition of bankruptcy is filed in any court of competent jurisdiction by such other Party; or (iii) this Agreement is assigned by such other Party for the benefit of
creditors. 

  

	 	24.3	If either Party breaches this Agreement, the other Party may terminate this agreement if the breaching Party does not cure the breach within [***] of written notice of the same. Termination will be without prejudice to
any rights that may have been accrued to either Party before termination. Cure of a breach under this Section 24.3 will not be available under the following Sections 24.4-24.7. 

 

	 	24.4	Client may terminate this Agreement upon [***] written notice in the event that FDA or any other governmental agency takes any action, or raises any objection, that prevents the Client from importing, exporting,
purchasing or selling Commercial Product. 

  

	 	24.5	Client may terminate this Agreement upon [***] written notice in the event that PYRAMID has [***] within the same Calendar Year. 

  

	 	24.6	Client may terminate this Agreement upon [***] written notice in the event that PYRAMID does not have suitable Total Available Capacity to deliver Client’s Rolling Forecast or Long-Term Forecast. 

 

	 	24.7	Client may terminate this Agreement upon [***] written notice in the event that PYRAMID and Client cannot agree on revised pricing resulting from any requested Specification change as further defined in Section 5.

  

	 	24.8	Except for expiration or termination of this Agreement for reasons stated in Sections 24.2 and 24.3, Client shall have the option to secure and PYRAMID shall agree to supply, an additional inventory of Commercial
Product [***] according to a delivery schedule agreeable to both Parties. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 20
 of 27

  

	 	24.9	Upon expiration or termination of this Agreement for any reason, PYRAMID will return, at Client’s expense, all Client Materials, Client equipment and Client documentation. In addition, the Parties will return to
each all copies of the other Party’s Information except for one copy that may be retained for the sole purpose of determining continuing obligations under Section 15. 

 

	 	24.10	Client shall provide at least [***] prior notice if it intends to no longer order a Commercial Product due to discontinuance of the Commercial Product in the market. 

 

	25.	GENERAL 

  

	 	25.1	Assignment; Subcontractors. Neither Party will transfer or assign its rights or obligations under this Agreement, in whole or in part, without the other Party’s prior written permission; provided, however, that
Client may assign its rights and obligations under this Agreement to any Affiliate without PYRAMID’s prior consent but must give PYRAMID written notice of such assignment within [***] following the assignment. PYRAMID may not utilize
subcontractors to perform any part of the Services without prior written authorization by Client. All assignees must comply with the terms of this Agreement. 

  

	 	25.2	[***]. 

  

	 	25.3	Entire Agreement; Amendments. The provisions, terms and conditions of this Agreement (including its Schedules and any subsequent Purchase Orders) constitute the entire agreement of the Parties with regard to the subject
matter of this Agreement and supersede any prior agreements whether oral or written. No waiver, modification, change or amendment of any of the provisions of this Agreement shall be valid unless in writing and signed by the Party against whom such
claimed waiver, modification, change or amendment is sought to be enforced. The terms of this Agreement shall supersede any subsequent Schedules or Purchase Orders in the event of inconsistencies with the terms of this Agreement. 

 

	 	25.3	Notices. All notices, requests, demands and other communications required or permitted to be given hereunder will be in writing and will be deemed to have been given (a) when received, if delivered in person, or
(b) three (3) business days following the mailing thereof, if mailed by certified first class mail, postage prepaid, return receipt requested, in any such case as follows: 

If to Client: 

Xeris Pharmaceuticals, Inc. 

180 N. LaSalle Street, Suite 1800 

Chicago, Illinois 6060 
  

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 21
 of 27

  

			
		 	 Attn.: COO & General Counsel

		
	 If to PYRAMID:
	 	 PYRAMID Laboratories, Inc.

		 	 3598 Cadillac Ave.

		 	 Costa Mesa, California 92626

		 	Attn.: President & CEO

  

	 	25.4	Severability. If any term or provision of this Agreement is invalid or unenforceable, the remainder of this Agreement shall be unaffected thereby and each remaining term or provision of this Agreement is valid and will
be enforceable to the fullest extent permitted by law. 

  

	 	25.5	Waiver. The failure of either Party to insist upon strict observation or performance of any provision of this Agreement, or to exercise any right or remedy shall not impair or waive any such right or remedy in the
future. Every right and remedy given by this Agreement to the Parties may be exercised from time to time as often as appropriate. All remedies, either under this Agreement or by law or otherwise afforded, will be cumulative and not alternative.

  

	 	25.6	Force Majeure. Neither Party will be liable nor deemed to be in default for any delay or failure in performance under this Agreement or other interruption of service or employment deemed resulting directly or indirectly
from Acts of God, civil or military authority, acts of public enemy, war, accident, fire, explosion, earthquake, flood, failure of transportation, strike, or other work interruption by either party’s employees or any similar or dissimilar cause
beyond the reasonable control of either Party. 

  

	 	25.7	Binding Effect. This Agreement will be binding upon and will inure to the benefit of Client and PYRAMID, their respective successors and permitted assigns. 

 

	 	25.8	Arbitration. Any dispute, controversy or claim arising out of or related to this Agreement, or the breach thereof, shall be settled by binding arbitration in accordance with the Commercial Rules of the American
Arbitration Association, and judgment upon any arbitration award rendered hereunder may be entered in any court having jurisdiction. Each Party shall select one (1) neutral arbitrator from a list provided by the American Arbitration Association
and those two arbitrators shall select a third arbitrator from the list. The arbitration process shall take place in Delaware, or such other place as the Parties may hereafter agree. The prevailing Party shall have the costs for the arbitration,
including attorneys’ fees, paid by the non-prevailing Party. 

  

	 	25.9	Governing Law. This Agreement is to be construed and determined under the laws of the State of Delaware. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 22
 of 27

  

	 	25.10	Headings. The headings of this Agreement are inserted merely for convenience and ease of reference and will not affect or modify the meaning of any of the terms, covenants or conditions of this
Agreement.  

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 23
 of 27

  

 IN WITNESS WHEREOF, the parties have executed this Agreement in duplicate originals by their duly
authorized representatives. 
  

									
	PYRAMID Laboratories Inc.	 		 	Xeris Pharmaceuticals, Inc.
					
	By:	 	  
	 	            	 	By:	 	  

	Name:	 	Medhat Gorgy	 		 	Name:	 	Paul Edick
	Title:	 	President& CEO	 		 	Title:	 	CEO
	Date:	 	  
	 		 	Date:	 	  

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 24
 of 27

  

 Schedule A 

Batch Size, Dosage, Yield*, Volume, Pricing 
  

					
	 [***]
	  		  	
			
	 [***]
	  		  	
			
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  		  	
			
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  		  	
			
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  		  	
			
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
			
	 [***].
	  		  	

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 25
 of 27

  

 Schedule A (continued) 

Batch Size, Dosage, Yield, Volume Pricing 

Pricing Assumptions: 
  

	1.	Standard Batch [***]. 

  

	2.	Standard batch size estimates based on [***] theoretical yield per dosage; yield assumptions and batch sizes shall be adjusted annually based on actual production history. 

 

	3.	Batch size/yield/price independent [***]. 

  

	4.	Pricing subject to annual adjustments as defined under Section 3.3.2, [***]. 

  

	5.	Pricing for Validation Batches shall be adjusted as defined under Section 3.3.3 [***]. 

  

	6.	Price includes [***]. 

  

	7.	Price includes [***]. 

  

	8.	Price excludes [***]. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 26
 of 27

  

 Schedule B 

Client Materials 
  

							
	 Name
	  	 Description
	  	 Client Specification
	  	 
	 [***]
	  	[***]	  	[***]	  	
				
	 [***]
	  	[***]	  	[***]	  	
		  	[***]	  		  	
		  	[***]	  		  	
		  	[***]	  		  	
				
	 [***]
	  	[***]	  	[***]	  	
		  	[***]	  		  	
		  	[***]	  		  	
		  	[***]	  		  	
				
	 [***]
	  	[***]	  	[***]	  	
		  	[***]	  		  	
		  	[***]	  		  	
				
	 [***]
	  	[***]	  		  	
		  	[***]	  	[***]	  	

 Specifications for each Client Material shall be updated from time to time as required in accordance with provisions of the
Quality Agreement. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 27
 of 27

  

 Schedule C 

Commercial Products 
  

							
	 Client Part Number
	  	 Description
	  	 	  	 
	[***]	  	[***]	  		  	
				
	[***]	  	[***]	  		  	
				
	[***]	  	[***]	  		  	
				
	[***]	  	[***]	  		  	

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}]]